BioCentury
ARTICLE | Clinical News

AUT00206: Additional Ph Ia data

January 20, 2017 9:32 PM UTC

Data from 32 evaluable healthy volunteers in a double-blind, placebo-controlled, U.K. Phase Ia trial showed that oral AUT00206 significantly reduced Mismatch Negativity (MMN) latency at 8 hours post-d...

BCIQ Company Profiles

Autifony Therapeutics Ltd.

BCIQ Target Profiles

Potassium channel Kv3